SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.
作者信息
Walensky Rochelle P, Walke Henry T, Fauci Anthony S
机构信息
Centers for Disease Control and Prevention, Atlanta, Georgia.
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
出版信息
JAMA. 2021 Mar 16;325(11):1037-1038. doi: 10.1001/jama.2021.2294.
Abstract
摘要
相似文献
1
SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.美国关注的严重急性呼吸综合征冠状病毒2变种——挑战与机遇
JAMA. 2021 Mar 16;325(11):1037-1038. doi: 10.1001/jama.2021.2294.
2
Will SARS-CoV-2 variants of concern affect the promise of vaccines?高关注变异株会影响疫苗的效果吗？
Nat Rev Immunol. 2021 Jun;21(6):340-341. doi: 10.1038/s41577-021-00556-5.
3
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.针对 SARS-CoV-2 及其变体的多样化疫苗平台。
Expert Rev Vaccines. 2022 Jan;21(1):47-67. doi: 10.1080/14760584.2022.1997601. Epub 2022 Jan 11.
4
New SARS-CoV-2 Variants Challenge Vaccines Protection.新型新冠病毒变种对疫苗保护构成挑战。
AIDS Rev. 2021 Feb 22;23(1):57-58. doi: 10.24875/AIDSRev.M21000040.
5
A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States.美国 SARS-CoV-2 遗传监测和多样性的疫苗接种前基线。
Viruses. 2022 Jan 7;14(1):104. doi: 10.3390/v14010104.
6
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.灭活新冠病毒疫苗第三次加强剂量引发的抗体反应可中和新冠病毒变异株。
Emerg Microbes Infect. 2021 Dec;10(1):2125-2127. doi: 10.1080/22221751.2021.1996210.
7
Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis.疫苗接种后迅速放宽大流行限制有利于 SARS-CoV-2 变体的增长：基于模型的分析。
PLoS One. 2021 Nov 24;16(11):e0258997. doi: 10.1371/journal.pone.0258997. eCollection 2021.
8
The variants of SARS-CoV-2 and the challenges of vaccines.SARS-CoV-2 的变异株和疫苗的挑战。
J Med Virol. 2022 Apr;94(4):1366-1372. doi: 10.1002/jmv.27513. Epub 2021 Dec 15.
9
Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.墨西哥蒙特雷一家医院 COVID-19 突破性感染中关注的 SARS-CoV-2 变异株和感兴趣的变异株的流行情况。
Viruses. 2022 Jan 14;14(1):154. doi: 10.3390/v14010154.
10
[Mutations, variants and strains of SARS-CoV-2].[严重急性呼吸综合征冠状病毒2的突变、变体和毒株]
Semergen. 2021 Apr;47(3):208-209. doi: 10.1016/j.semerg.2021.01.001. Epub 2021 Jan 28.
引用本文的文献
1
A network-based model to assess vaccination strategies for the COVID-19 pandemic by using Bayesian optimization.一种基于网络的模型，用于通过贝叶斯优化评估针对新冠疫情的疫苗接种策略。
Chaos Solitons Fractals. 2024 Apr;181. doi: 10.1016/j.chaos.2024.114695. Epub 2024 Mar 14.
2
An Update on RNA Virus Discovery: Current Challenges and Future Perspectives.RNA病毒发现的最新进展：当前挑战与未来展望
Viruses. 2025 Jul 15;17(7):983. doi: 10.3390/v17070983.
3
Virus-specific host responses and gene signatures following infection with major SARS-CoV-2 variants of concern: role of ZBP1 in viral clearance and lung inflammation.感染主要关注的SARS-CoV-2变异株后的病毒特异性宿主反应和基因特征：ZBP1在病毒清除和肺部炎症中的作用
Front Immunol. 2025 May 9;16:1557535. doi: 10.3389/fimmu.2025.1557535. eCollection 2025.
4
Severe Acute Respiratory Syndrome Coronavirus 2 Variant Infection Dynamics and Pathogenesis in Transgenic K18-h and Inbred Immunocompetent C57BL/6J Mice.严重急性呼吸综合征冠状病毒2变异株在转基因K18-h和近交免疫活性C57BL/6J小鼠中的感染动态及发病机制
Viruses. 2025 Mar 30;17(4):500. doi: 10.3390/v17040500.
5
Knowledge, attitudes and barriers to uptake of COVID-19 vaccine in Uganda, February 2021.2021年2月乌干达民众对新冠疫苗的认知、态度及接种障碍
BMJ Glob Health. 2025 Mar 26;10(3):e016959. doi: 10.1136/bmjgh-2024-016959.
6
Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases.熊去氧胆酸可缓解慢性肝病患者新冠病毒病的临床严重程度。
Front Med (Lausanne). 2025 Feb 6;12:1494248. doi: 10.3389/fmed.2025.1494248. eCollection 2025.
7
Difference in Optical Coherence Tomography Angiography Parameters After SARS-CoV-2 Infection During the Alpha and Delta Variant Dominance Periods.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染后在阿尔法和德尔塔变异株主导时期光学相干断层扫描血管造影参数的差异
Viruses. 2024 Dec 31;17(1):47. doi: 10.3390/v17010047.
8
Comprehensive Analysis of the Immune Response to SARS-CoV-2 Epitopes: Unveiling Potential Targets for Vaccine Development.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）表位免疫反应的综合分析：揭示疫苗开发的潜在靶点
Biology (Basel). 2025 Jan 14;14(1):67. doi: 10.3390/biology14010067.
9
Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review.重新审视天然抗菌肽对新发呼吸道病毒疾病的潜力：综述
3 Biotech. 2025 Feb;15(2):40. doi: 10.1007/s13205-024-04184-3. Epub 2025 Jan 13.
10
Phylodynamic analysis reveals disparate transmission dynamics of -complex lineages in Botswana.系统动力学分析揭示了博茨瓦纳不同谱系的传播动态。
medRxiv. 2024 Nov 2:2024.10.31.24316225. doi: 10.1101/2024.10.31.24316225.
本文引用的文献
1
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.美国出现并迅速传播 SARS-CoV-2 变异株 B.1.1.7。
Cell. 2021 May 13;184(10):2587-2594.e7. doi: 10.1016/j.cell.2021.03.052. Epub 2021 Mar 30.
2
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
3
First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota - December 2020-January 2021.明尼苏达州 2020 年 12 月至 2021 年 1 月期间发现的首例 SARS-CoV-2 变异株 B.1.1.7 。
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):278-279. doi: 10.15585/mmwr.mm7008e1.
4
Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020.检测到 B.1.351 新型 SARS-CoV-2 变异株-赞比亚，2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):280-282. doi: 10.15585/mmwr.mm7008e2.
5
Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021.SARS-CoV-2 B.1.1.7 谱系的出现 - 美国，2020 年 12 月 29 日-2021 年 1 月 12 日。
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99. doi: 10.15585/mmwr.mm7003e2.
Zotero 插件